<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00352677</url>
  </required_header>
  <id_info>
    <org_study_id>INNO-406</org_study_id>
    <nct_id>NCT00352677</nct_id>
  </id_info>
  <brief_title>Safety and Tolerability Study of INNO-406 to Treat Chronic Myeloid Leukemia or Acute Lymphocytic Leukemia</brief_title>
  <official_title>A Phase I, Open-Label, Dose Escalation Study to Evaluate the Safety, Tolerability and Pharmacokinetics of INNO-406 in Adult Patients With Imatinib-Resistant or Intolerant Philadelphia Chromosome-Positive (Ph+) Leukemias</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>CytRx</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>CytRx</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine the safety and effectiveness of INNO-406 in adult&#xD;
      patients with imatinib-resistant or intolerant Philadelphia chromosome-positive (Ph+)&#xD;
      leukemias.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The purpose of this study is to determine the safety, tolerability and pharmacokinetic&#xD;
      profile of INNO-406 when administered as a daily oral agent in adult patients with&#xD;
      imatinib-resistant or intolerant Philadelphia chromosome-positive (Ph+) leukemias.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>July 2006</start_date>
  <completion_date type="Actual">May 2008</completion_date>
  <primary_completion_date type="Actual">May 2008</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To determine the maximum tolerated dose (MTD) and dose limiting toxicity (DLT) of INNO-406 when administered as a single agent to adult patients with imatinib-resistant or intolerant Ph+ leukemias.</measure>
    <time_frame>One year</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>To determine the safety profile (including acute and chronic toxicities) and tolerability of INNO-406 in this patient population.</measure>
    <time_frame>One year</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>To determine the pharmacokinetic (PK) profile of INNO-406.</measure>
    <time_frame>One year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To assess BCR-ABL transcript levels and to analyze BCR-ABL mutations.</measure>
    <time_frame>One year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To assess leukemia response rates in this patient population.</measure>
    <time_frame>One year</time_frame>
  </secondary_outcome>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Chronic Myeloid Leukemia</condition>
  <condition>Acute Lymphocytic Leukemia</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>INNO-406</intervention_name>
    <description>Oral, twice daily self-administration of 10 mg and/or 50 mg tablets</description>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Have a confirmed diagnosis of Ph+ ALL or CML in chronic, accelerated, or blastic&#xD;
             phases that are either resistant to or intolerant of imatinib therapy.&#xD;
&#xD;
          2. Be ≥18 years old.&#xD;
&#xD;
          3. Have an Eastern Cooperative Oncology Group (ECOG) Performance Status of ≤2.&#xD;
&#xD;
          4. Have an estimated life expectancy of ≥12 weeks.&#xD;
&#xD;
          5. Be male or non-pregnant, non-lactating female. Patients who are fertile must agree to&#xD;
             use an effective barrier method of contraception while on therapy and for 90 days&#xD;
             following discontinuation of study drug.&#xD;
&#xD;
          6. Have a negative serum or urine pregnancy test within 7 days prior to the first dose of&#xD;
             study drug (if patient is a female of childbearing potential).&#xD;
&#xD;
          7. Have acceptable pre-treatment clinical laboratory results.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Have received chemotherapy ≤1 week from the start of therapy, with the exception of&#xD;
             hydroxyurea and corticosteroids.&#xD;
&#xD;
          2. Have received imatinib ≤3 days prior to enrollment or have not recovered from side&#xD;
             effects of imatinib therapy.&#xD;
&#xD;
          3. Have impaired cardiac function.&#xD;
&#xD;
          4. Have an active, uncontrolled systemic infection considered opportunistic,&#xD;
             life-threatening, or clinically significant at the time of treatment.&#xD;
&#xD;
          5. Have clinically significant acute or chronic liver or renal disease considered&#xD;
             unrelated to tumor.&#xD;
&#xD;
          6. Have impaired gastrointestinal function that may significantly alter drug absorption&#xD;
             (e.g., uncontrolled vomiting, ulcerative colitis, malabsorption, or small bowel&#xD;
             resection).&#xD;
&#xD;
          7. Are pregnant or lactating.&#xD;
&#xD;
          8. Have psychiatric disorder(s) that would interfere with consent, study participation,&#xD;
             or follow-up.&#xD;
&#xD;
          9. Have not recovered from acute toxicity of all previous therapy prior to enrollment.&#xD;
&#xD;
         10. Have any other severe concurrent disease and/or uncontrolled medical conditions,&#xD;
             which, in the judgment of the investigator, could predispose patients to unacceptable&#xD;
             safety risks or compromise compliance with the protocol.&#xD;
&#xD;
         11. Have a history of another primary malignancy that is currently clinically significant&#xD;
             or requires active intervention.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Hagop Kantarjian, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Texas, MD Anderson Cancer Center, Houston, TX 713-792-7026 hkantarj@mdanderson.org</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>H. Lee Moffitt Cancer Center and Research Institute</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33612</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Texas MD Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Charite University of Medicine</name>
      <address>
        <city>Berlin</city>
        <zip>13353</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Johann Wolfgang Goethe Universität</name>
      <address>
        <city>Frankfurt am Main</city>
        <zip>60590</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Heidelberg Medical Clinic</name>
      <address>
        <city>Mannheim</city>
        <zip>68305</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chaim Sheba Medical Center</name>
      <address>
        <city>Tel Hashomer</city>
        <zip>52621</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
    <country>Israel</country>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2009</verification_date>
  <study_first_submitted>July 14, 2006</study_first_submitted>
  <study_first_submitted_qc>July 14, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 17, 2006</study_first_posted>
  <last_update_submitted>May 29, 2009</last_update_submitted>
  <last_update_submitted_qc>May 29, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 1, 2009</last_update_posted>
  <responsible_party>
    <name_title>Michael Dowd, Director, Product Development</name_title>
    <organization>Innovive Pharmaceuticals</organization>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Leukemia, Myeloid</mesh_term>
    <mesh_term>Leukemia, Lymphoid</mesh_term>
    <mesh_term>Leukemia, Myelogenous, Chronic, BCR-ABL Positive</mesh_term>
    <mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bafetinib</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

